Chips Up, Biotech Lifted, Retail Revised

Analysts kept busy on Monday with target price adjustments across several key sectors.

NVDA received a fresh upward target price revision. The consensus average climbed to $327.65, up from $327.13. Short interest sits at just 1.2% of free float — bears have little grip on the AI chipmaker.

AMD moved in the opposite direction. Analysts trimmed the target to $612.62 from $613.84. The cut is modest but notable given AMD's push to grab AI accelerator market share from Nvidia. Short interest is only 2.5% of free float.

MRNA saw the most meaningful target lift. The consensus rose to $118.59 from $116.50. Moderna carries 13.4% short interest as a percentage of free float. That elevated short positioning makes any analyst upgrade more impactful — a squeeze potential lurks.

TGT got a target bump to $162.76. Analysts remain mixed on the retailer with 4 buys, 22 holds, and 11 sells. Consumer spending resilience appears to be driving cautious optimism.

GD also received a small target increase to $421.68. Defense spending momentum continues to support General Dynamics.

CMS was the notable downgrade story. Analysts cut the target slightly to $79.17 for the utility. With rate uncertainty lingering, regulated utilities face margin pressure.